These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12445410)

  • 1. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.
    Terg R; Coronel E; Sordá J; Muñoz AE; Findor J
    J Hepatol; 2002 Dec; 37(6):717-22. PubMed ID: 12445410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.
    Wolfhagen FH; Sternieri E; Hop WC; Vitale G; Bertolotti M; Van Buuren HR
    Gastroenterology; 1997 Oct; 113(4):1264-9. PubMed ID: 9322521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
    Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.
    Bergasa NV; Alling DW; Talbot TL; Wells MC; Jones EA
    J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):431-4. PubMed ID: 10459118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.
    Jones EA; Dekker LR
    Gastroenterology; 2000 Feb; 118(2):431-2. PubMed ID: 10648471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral naltrexone on pruritus in cholestatic patients.
    Mansour-Ghanaei F; Taheri A; Froutan H; Ghofrani H; Nasiri-Toosi M; Bagherzadeh AH; Farahvash MJ; Mirmomen S; Ebrahimi-Dariani N; Farhangi E; Pourrasouli Z
    World J Gastroenterol; 2006 Feb; 12(7):1125-8. PubMed ID: 16534857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.
    Pauli-Magnus C; Mikus G; Alscher DM; Kirschner T; Nagel W; Gugeler N; Risler T; Berger ED; Kuhlmann U; Mettang T
    J Am Soc Nephrol; 2000 Mar; 11(3):514-519. PubMed ID: 10703675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy.
    Neuberger J; Jones EA
    Eur J Gastroenterol Hepatol; 2001 Nov; 13(11):1393-4. PubMed ID: 11692070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study.
    Hamann S; Sloan P
    J Opioid Manag; 2007; 3(3):137-44. PubMed ID: 18027539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases.
    Metze D; Reimann S; Beissert S; Luger T
    J Am Acad Dermatol; 1999 Oct; 41(4):533-9. PubMed ID: 10495371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
    Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
    Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
    Müller C; Pongratz S; Pidlich J; Penner E; Kaider A; Schemper M; Raderer M; Scheithauer W; Ferenci P
    Eur J Gastroenterol Hepatol; 1998 Oct; 10(10):865-70. PubMed ID: 9831410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised crossover trial of naltrexone in uraemic pruritus.
    Peer G; Kivity S; Agami O; Fireman E; Silverberg D; Blum M; laina A
    Lancet; 1996 Dec; 348(9041):1552-4. PubMed ID: 8950882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
    Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
    J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone: a case report of pruritus from an antipruritic.
    Sullivan JR; Watson A
    Australas J Dermatol; 1997 Nov; 38(4):196-8. PubMed ID: 9431714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients].
    Brune A; Metze D; Luger TA; Ständer S
    Hautarzt; 2004 Dec; 55(12):1130-6. PubMed ID: 15517116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.
    Bergasa NV; Alling DW; Talbot TL; Swain MG; Yurdaydin C; Turner ML; Schmitt JM; Walker EC; Jones EA
    Ann Intern Med; 1995 Aug; 123(3):161-7. PubMed ID: 7598296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N; Sun S; Johnson F; Stauffer J
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.